News

News

December 24, 2013
December 11, 2013 - Yoshihiro Miwa, President & C.E.O. of KOWA, was honored the chair engraved with the Brigham and Women’s Hospital (BWH) logo. This chair indicates the contribution toward the medical development from BWH that operates joint research facility with KOWA.
October 26, 2012
License Agreement of SGLT2 Inhibitor "CSG452" in Japan
June 06, 2012
A consolidated subsidiary of Mitsubishi Tanabe Pharma, Tai Tien Pharmaceuticals Co., Ltd., started marketing Livalo (pitavastatin), a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor), in Taiwan on June 1, 2012.
A regulatory approval was obtained in January 2011.
May 09, 2012
A consolidated subsidiary of Mitsubishi Tanabe Pharma,P.T. Tanabe Indonesia,started marketing Livalo (pitavastatin),a hypercholesterolemia treatment agent (an HMG-CoA reductase inhibitor),in Indonesia on May 1,2012.
The launch comes after P.T. Tanabe Indonesia received regulatory approval in November 2011.
February 20, 2012
Eli Lilly has introduced Redevant (pitavastatin), an HMG-CoA reductase inhibitor for lowering cholesterol, in Mexico this month.
The launch comes after the product received approval in July 2011 from the country's Ministry of Health.
November 10, 2011
Kowa Announces the Efficacy and Safety of a Novel Phosphodiesterase 3 Inhibitor K-134 for the Treatment of Intermittent Claudication in AHA 2011
August 04, 2011
Mexican health authority has granted marketing authorization for pitavastatin,an HMG-CoA reductase inhibitor or statin,for treatment of hyperlipidemia.
Kowa’s partner,Eli Lilly will market the product as Redevant® from early 2012.
May 11, 2011
The HMG-CoA reductase inhibitor pitavastatin calcium (Livazo 1mg, 2mg & 4mg) has been launched in Spain on May 2, 2011 as the first European market.
Spain is co-marketed by Recordati S.p.A and ESTEVE
May 09, 2011
Kowa Announces the Efficacy and Safety of a Novel Rho Kinase Inhibitor (K-115) in the Treatment of Glaucoma-The Association for Research in Vision and Ophthalmology (ARVO) 2011-
April 28, 2011
Contracts of BBHP (Bare Boat Hire & Purchase) have been entered into successfully with Adani Group for 2 bulk carrier vessels of Cape-size.
The BBHP being effective for 10 years period to the 2 vessels, each with 180,000 DWT type bulk carrier respectively and will be completed its construction in the year of 2012, which we have worked it for these months with Adani Group, now has been mutually agreed in final and signed on April 28, 2011.
We shall proceed and develop our business more and more at the various sites of business with Adani Group.
January 28, 2011
We have made and entered into a Contract of "Business Alliance" on Jan.28, 2011, with Adani Group who is one of India's fastest-growing business houses.
By the contract we will act as the navigator for any of Japanese companies and manufacturers who intend to advance to the Economic Free Zone that is developed and managed by Adani Group in India.
And furthermore we will act as the coordinator for any of Japanese companies who desire to sell or buy any products procured by Adani Group.
We will contribute, so as above, in aggressive attitude, to any of penetration, investment, and/or products-export/import, to/from India for the benefit of Japanese enterprises.
January 24, 2011
Subgroup Analyses of Peretinoin (NIK-333) Phase II/III Trial in Patients Following Curative Therapy for Hepatocellular Carcinoma (HCC) Indicate Populations Who May Gain Most Benefit from Peretinoin Therapy.
Peretinoin may reduce de novo carcinogenesis.
Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011
January 19, 2011
Peretinoin (NIK-333) Study Subanalysis Gives Clue To Mechanism of Reduced Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at American Society of Clinical Oncology Gastrointestinal Cancers Symposium 2011
December 14, 2010
Kowa Group Website Launch!
October 20, 2010
Peretinoin(NIK-333)Data, the Results of the Clinical Pharmacology Study for Liver Gene Expression Profiles in Patients after Curative Therapy of Hepatocellular Carcinoma (HCC), To Be Presented at The 61st Annual Meeting of the American Association for the Study of Liver Diseases
September 13, 2010
Peretinoin reduces recurrence risk of hepatocellular carcinoma after curative therapy
The results of a Phase II/III trial presented at the International Liver Cancer Association Fourth Annual Conference
August 30, 2010
Peretinoin(NIK-333)Data, the Results of the Phase II/III Trial for the Suppression of Recurrence of Hepatocellular Carcinoma (HCC), To Be Presented at the International Liver Cancer Association Annual Conference
July 29, 2010
New English Website Launch!
July 29, 2010
New Telephoto Scope will be exhibited !!
  • British Birdwatching Fair 2010 (BBWF)
  • August 20-22, 2010
  • Rutland Water (U.K.)
July 29, 2010
New 2D/3D Non-mydriatic retinal camera "nonmydWX" will be exhibited!
  • European Society of Cataract & Refractive Surgerons(ESCRS 2010)
  • September 4-8, 2010
  • Paris(France)
July 29, 2010
New 2D/3D Non-mydriatic retinal camera "nonmydWX" will be exhibited!
  • Asia Pacific Academy of Ophthalmology(APAO 2010)
  • September 16-20, 2010
  • Beijing(China)
July 29, 2010
New Telephoto Scope will be exhibited !!
  • Photokina 2010
  • September 21-26, 2010
  • Cologne (Germany)
July 29, 2010
Several New Products will be exhibited !!
  • Security Essen 2010
  • October 5-8, 2010
  • Essen(Germany)
July 29, 2010
Several New Products will be exhibited !!
  • ASIS 2010
  • October 12-14, 2010
  • Dallas(U.S.A.)
July 29, 2010
New 2D/3D Non-mydriatic retinal camera "nonmydWX" will be exhibited!
  • American Academy of Ophthalmology(AAO 2010)
  • October 16-19, 2010
  • Chicago(U.S.A.)
December 24, 2009
Kowa Company, Ltd. Opens Collaborative Cardiovascular Research Center with Brigham and Women's Hospital
Kowa Company, Ltd. headquartered in Nagoya, Japan (Kowa) and Brigham and Women's Hospital (BWH), December 23, 2009, open The Center for Interdisciplinary Cardiovascular Sciences (CICS) in the Center for Life Science, 3 Blackfan Street in the Longwood Medical Area of Boston.
CICS is collaborative research center where scientists from Kowa and BWH as a Harvard-affiliated hospital will work collaboratively for discovery and advancement in cardiovascular research.
August 3, 2009
FDA Approves LIVALO® for Primary Hypercholesterolemia and Combined Dyslipidemia
FDA Approves LIVALO® for Primary Hypercholesterolemia and Combined Dyslipidemia.
Montgomery, AL and Morrisville, NC August 03, 2009 - Kowa Research Institute (KRI)based in Morrisville, NC and Kowa Pharmaceuticals America, Inc. (KPA), a privately-held specialty pharmaceutical company headquartered in Montgomery, AL, announced today that the U.S. Food and Drug Administration (FDA) has approved LIVALO® (pitavastatin), a potent HMG-CoA reductase inhibitor (statin), for the primary treatment of hypercholesterolemia and combined dyslipidemia.
September 24, 2008
Kowa and Teva Announce Strategic Partnership to Create a Leading Generic Pharmaceutical Company in Japan
Kowa Company, Ltd. headquartered in Nagoya, Japan (Kowa) and Teva Pharmaceutical Industries Ltd. today announced that they have signed a definitive agreement to establish a leading generic pharmaceutical company in Japan. Each company will have a 50% stake in Teva-Kowa Pharma Co.,Ltd., which will become operational in 2009.
The new company, Teva-Kowa Pharma Co., Ltd. will supply high quality generic pharmaceutical products for the Japanese market by taking advantage of capabilities of each company in the marketing, research and development, manufacturing and distribution.
August 4, 2008
Kowa Company, Ltd. Acquires ProEthic Pharmaceuticals, Inc.
Kowa Company, Ltd., a privately-held company headquartered in Nagoya, Japan (Kowa), August 4, 2008, announced the acquisition of ProEthic Pharmaceuticals, Inc., a privately-held specialty pharmaceutical company based in Montgomery, Alabama.
Effective September 1, 2008, ProEthic will change name to Kowa Pharmaceuticals America, Inc.(KPA) and will assume responsibility for all sales and marketing functions currently operating in the U.S.

To visit KPA's Web Site, Please click here: Kowa Pharmaceuticals America, Inc.(KPA)
July 1, 2007
Kowa Company, Ltd. Assumes the Business from Kowa Parmaceutical Co. Ltd.
All of the business of Kowa Pharmaceutical Company Ltd. relating to its business in the areas of the research, development and manufacturing (but excluding any of its business involving its commercial distribution and sales-related activities) has been separated from Kowa Pharmaceutical Company Ltd. and transferred into Kowa Company Ltd.
October 1, 2006
Kowa Company, Ltd. Acquires Nikken Chemicals
Kowa Company, Ltd.(Kowa) acquires the remaining common shares of Nikken Chemicals, bringing its ownership to 100%, and the two companies consolidate all of their ethical drug sales business into Nikken Chemicals, which becomes Kowa's wholly-owned subsidiary and is re-named Kowa Pharmaceutical Co. Ltd.
November 1, 2005
Kowa Company, Ltd.(Kowa) and Nikken Chemicals jointly announced to strengthen sales collaborations in Japan.
June 1, 2005
Kowa Company, Ltd.(Kowa) has acquired the principle OTC business of Dainippon Pharmaceutical Co. Ltd. and Marupi Drug Co., Ltd.
January 20, 2004
Kowa Company, Ltd.(Kowa) and Nikken Chemicals enter into co-promotion agreement of the antihypertensive agent olmesartan medoxiomil, which is licensed from Sankyo.
November 25, 2003
Kowa Company, Ltd.(Kowa) enters into an agreement with Kowa Shinyaku Company, Ltd. to integrate ethical drugs business effective from April 2004.
October 21, 2003
Kowa Company, Ltd.(Kowa) commences tender offer for shares of Nikken Chemicals.
September 12, 2003
Kowa Company, Ltd.(Kowa) launches the HMG-CoA reductase inhibitor LIVALO 1mg & 2mg in Japan.
August 18, 2003
Kowa Company, Ltd.(Kowa) enters into license & supply agreement of pitavastatin calcium (LIVALO) between Choongwae Pharma, South Korea.
July 17, 2003
The HMG-CoA reductase inhibitor LIVALO (pitavastatin calcium)1mg & 2mg have been approved in Japan.